country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-117582

Copy Link Print Information

Elvucitabine

Elvucitabine is an L-nucleoside analogue. Elvucitabine is a potent nucleoside reverse transcriptase (RT) inhibitor. Elvucitabine can be used in research of viral infection.

For research use only. We do not sell to patients.

CAS No.: 181785-84-2
Formula: C₉H₁₀FN₃O₃
Molecular Weight:227.19

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (266 KB)

Elvucitabine Chemical Structure

CAS No.: 181785-84-2

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- Clinical Trial
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Elvucitabine is an L-nucleoside analogue. Elvucitabine is a potent nucleoside reverse transcriptase (RT) inhibitor. Elvucitabine can be used in research of viral infection^[1].

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
B16	IC₅₀	>200 μM Compound: 1	In vitro inhibitory activity against growth of HIV infected B16 cell line In vitro inhibitory activity against growth of HIV infected B16 cell line	[PMID: 9873711]
CCRF-CEM	ED₅₀	>100 μM Compound: 2	In vitro concentration required to decrease 50% of mitochondrial DNA content in CEM cells In vitro concentration required to decrease 50% of mitochondrial DNA content in CEM cells	[PMID: 8627596]
CCRF-CEM	ED₅₀	7 μM Compound: 2	In vitro concentration required to inhibit 50% of CEM cell growth In vitro concentration required to inhibit 50% of CEM cell growth	[PMID: 8627596]
CCRF-CEM	IC₅₀	>100 μM Compound: RVT	Cytotoxicity was determined in CEM cells, relative to RVT Cytotoxicity was determined in CEM cells, relative to RVT	[PMID: 15081000]
CCRF-CEM	IC₅₀	0.46 μM Compound: beta-L-D4FC	Tested in vitro for anticancer activity against CEM cells Tested in vitro for anticancer activity against CEM cells	[PMID: 10072683]
CCRF-CEM	IC₅₀	13 μM Compound: 4	Tested for cytotoxicity in human T-cell lymphoblastic leukemia cell line (CEM) Tested for cytotoxicity in human T-cell lymphoblastic leukemia cell line (CEM)	[PMID: 9871628]
CCRF-CEM	IC₅₀	24 μM Compound: 1	In vitro inhibitory activity against growth of HIV infected CEM cells combined with murine CTLL-2T lymphoblast cell line In vitro inhibitory activity against growth of HIV infected CEM cells combined with murine CTLL-2T lymphoblast cell line	[PMID: 9873711]
CCRF-CEM	IC₅₀	6.5 μM Compound: 1	In vitro inhibitory activity against growth of HIV infected CEM cell line In vitro inhibitory activity against growth of HIV infected CEM cell line	[PMID: 9873711]
DLD-1	IC₅₀	>200 μM Compound: 1	In vitro inhibitory activity against growth of HIV infected DLD-1 cell line In vitro inhibitory activity against growth of HIV infected DLD-1 cell line	[PMID: 9873711]
HepG2	EC₅₀	17 nM Compound: 4	Tested for effective concentration against HBV treated with drug every 3 days for 9 days using human hepatoblastoma cell line HepG2 2.2.15 Tested for effective concentration against HBV treated with drug every 3 days for 9 days using human hepatoblastoma cell line HepG2 2.2.15	[PMID: 9871628]
HepG2	ED₅₀	2 nM Compound: 2	Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line	[PMID: 8627596]
HepG2	ED₅₀	2 nM Compound: 2	Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line	[PMID: 8627596]
HepG2	IC₅₀	>200 μM Compound: 1	In vitro inhibitory activity against growth of HIV infected HepG2 cell line In vitro inhibitory activity against growth of HIV infected HepG2 cell line	[PMID: 9873711]
HepG2	IC₅₀	118 μM Compound: beta-L-D4FC	Tested in vitro for anticancer activity against HepG2 cells Tested in vitro for anticancer activity against HepG2 cells	[PMID: 10072683]
LNCaP	IC₅₀	55.2 μM Compound: beta-L-D4FC	Tested in vitro for anticancer activity against LNCaP cells Tested in vitro for anticancer activity against LNCaP cells	[PMID: 10072683]
MCF7	IC₅₀	82.8 μM Compound: beta-L-D4FC	Tested in vitro for anticancer activity against MCF-7 cells Tested in vitro for anticancer activity against MCF-7 cells	[PMID: 10072683]
MT2	ED₅₀	0.09 μM Compound: 2	Concentration required to inhibit 50% of HIV activity in MT-2 cells Concentration required to inhibit 50% of HIV activity in MT-2 cells	[PMID: 8627596]
MT2	IC₅₀	9 μM Compound: 1	In vitro inhibitory activity against growth of HIV infected MT-2/IIIB cell line In vitro inhibitory activity against growth of HIV infected MT-2/IIIB cell line	[PMID: 9873711]
PC-3	IC₅₀	>100 μM Compound: beta-L-D4FC	Tested in vitro for anticancer activity against PC-3 cells Tested in vitro for anticancer activity against PC-3 cells	[PMID: 10072683]
Rat1	IC₅₀	>200 μM Compound: 1	In vitro inhibitory activity against growth of HIV infected Rat-1 cell line In vitro inhibitory activity against growth of HIV infected Rat-1 cell line	[PMID: 9873711]
SK-MEL-28	IC₅₀	>100 μM Compound: beta-L-D4FC	Tested in vitro for anticancer activity against SK-MEL-28 cells Tested in vitro for anticancer activity against SK-MEL-28 cells	[PMID: 10072683]
SK-MES-1	IC₅₀	99.1 μM Compound: beta-L-D4FC	Tested in vitro for anticancer activity against SK-MES-1 cells Tested in vitro for anticancer activity against SK-MES-1 cells	[PMID: 10072683]
Vero	IC₅₀	>100 μM Compound: RVT	Cytotoxicity was determined in Vero cells, relative to RVT Cytotoxicity was determined in Vero cells, relative to RVT	[PMID: 15081000]
Vero	IC₅₀	9.4 μM Compound: beta-L-D4FC	Tested in vitro for cytotoxicity against Vero cells Tested in vitro for cytotoxicity against Vero cells	[PMID: 10072683]

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 181785-84-2
Molecular Weight 227.19
Formula C₉H₁₀FN₃O₃
SMILES

O=C1N=C(C(F)=CN1[C@H]2O[C@H](C=C2)CO)N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocols

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (266 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Guedes AC, et, al. Microalgae as sources of high added-value compounds--a brief review of recent work. Biotechnol Prog. 2011 May-Jun;27(3):597-613. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote